STOCKHOLM — On May 2, 2022, CombiGene (“CombiGene”, “The Company”) announced that Alvar Grönberg will join the Company on May 2, 2022, when he takes up the position of Senior Project Manager.
Alvar Grönberg is a Doctor of Medical Science, Karolinska Institutet, Stockholm, and has extensive experience in several disease areas including metabolic diseases and rare diseases. Alvar’s experience ranges from early preclinical development to clinical trials from his work in academia and industry. He has worked at the National Cancer Institute, USA, Karolinska Institutet, Pharmacia/Biovitrum and in recent years has been active in biotech companies such as Lipopeptide AB/Pergamum AB and NeuroVive Pharmaceutical AB/Abliva AB.
“I am thrilled to join CombiGene at this very exciting stage in the company’s development”, said Alvar Grönberg. “Gene therapy holds a fantastic potential, and I am really looking forward to be part of this rapidly evolving field within the pharmaceutical industry.”
“One of CombiGene’s ambitions for 2022 is to expand our project portfolio with new and promising gene therapy candidates. Alvar Grönberg will be instrumental for the future development as CombiGene takes the next steps in the company’s development,” said Jan Nilsson, CombiGene CEO.